FT US Pharma and Biotech Summit
16-17 May, 2023, New York
Leading Life Sciences into the future
ICON is proud to sponsor the FT US Pharma and Biotech Summit (New York, 16-17 May) – two days of insightful analysis and discussion on key topics including drug discovery, clinical trials, market access and stakeholder engagement. As life sciences companies innovate and evolve in a disrupted world, industry leaders will gather in New York to address the challenges and opportunities of today and tomorrow, from building partnerships and developing new treatments to investing in technology and preparing for the next national health crisis. Join us in-person and online as we explore new frontiers for business and for healthcare.
Speakers will include the CEOs from Amgen, Roche, Regeneron, as well as senior executives from many other pharma and biotech companies including Eli Lilly, Takeda, BMS, Genmab, Moderna, AstraZeneca, Novartis, GSK, Novo Nordisk, Astellas, Pfizer, Merck, Novavax and others.
Panel: Partnerships – Capitalizing on collaboration (10.00 EST)
Working together to save the world from a pandemic is one thing. Working together for commercial gain is a whole different ball game. Hear from professionals involved in managing different kinds of partnerships, exploring the challenge of making them truly productive.
- What could be the legacy of partnerships during the pandemic?
- Where are the emerging opportunities for stakeholders to build partnerships?
- What kinds of issues can test trust and provision of resources in partnerships?
- Are we seeing a shift in the balance of in-house and outsourced R&D?
Panelists:
- Jens Bitsch-Norhave, Vice President, Transactions and Innovation Partnering, Johnson & Johnson Innovation
- Jennifer Wong, Global Head of Strategy and Business Transformation, R&D Data and Data Sciences, Sanofi
- George McMillan, Chief Commercial Officer, ICON
Moderator:
- Hannah Kuchler, Global Pharmaceuticals Correspondent, Financial Times
Mr. George A. McMillan
Chief Commercial Officer
Mr. George A. McMillan is Chief Commercial Officer of ICON. Mr. McMillan joined ICON in 2012 as Executive Vice President of Finance Operations, a position he held until he was appointed Chief Commercial Officer in March 2017. Prior to ICON, Mr. McMillan held senior executive positions in a variety of service and consulting companies, most recently as CFO of PharmaNet Development Group. He also served as CEO of Palladium Group, a global leader in corporate performance management software and consulting; CFO and CEO of CMGI, the internet holding company, for which he was named Mass HighTech Turnaround CEO of the Year. Mr. McMillan was also CEO of BMG Direct, the North American music distribution division of Bertelsmann, A.G., and CFO/COO of Renaissance Solutions, a strategic consulting and technology services company. George holds a Bachelor of Arts degree in Economics from Stanford University, a Doctor of Law from Harvard Law School and a Masters of Business Administration from Harvard Business School.